R

Rekah Pharmaceutical Industry Ltd
TASE:REKA

Watchlist Manager
Rekah Pharmaceutical Industry Ltd
TASE:REKA
Watchlist
Price: 1 373 ILS -0.79% Market Closed
Market Cap: 162.5m ILS
Have any thoughts about
Rekah Pharmaceutical Industry Ltd?
Write Note

Rekah Pharmaceutical Industry Ltd
Cash from Financing Activities

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Rekah Pharmaceutical Industry Ltd
Cash from Financing Activities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cash from Financing Activities CAGR 3Y CAGR 5Y CAGR 10Y
R
Rekah Pharmaceutical Industry Ltd
TASE:REKA
Cash from Financing Activities
-â‚Ş55m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Teva Pharmaceutical Industries Ltd
TASE:TEVA
Cash from Financing Activities
-$2.3B
CAGR 3-Years
-11%
CAGR 5-Years
-10%
CAGR 10-Years
0%
Sol Gel Technologies Ltd
NASDAQ:SLGL
Cash from Financing Activities
$90k
CAGR 3-Years
4%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
I
InterCure Ltd
TASE:INCR
Cash from Financing Activities
-â‚Ş82.9m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Mediwound Ltd
NASDAQ:MDWD
Cash from Financing Activities
-$1.7m
CAGR 3-Years
-31%
CAGR 5-Years
-77%
CAGR 10-Years
N/A
S
Seach Medical Group Ltd
TASE:SEMG
Cash from Financing Activities
-â‚Ş3.4m
CAGR 3-Years
15%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Rekah Pharmaceutical Industry Ltd
Glance View

Market Cap
162.5m ILS
Industry
Pharmaceuticals

Rekah Pharmaceutical Industry Ltd. engages in the manufacture, import, marketing, sale, registration, and distribution of generic drugs, cosmetics, vitamins, and nutritional supplements. The firm operates two Good Manufacturing Practice (GMP) approved manufacturing sites, it has a marketing and distribution arm, a chain of pharmacies, and an export import unit. Rekah's plant covers approximately 5,000 square meters and was designed to take advantage of the most advanced and automated packaging techniques available. In April 1995, Rekah received the approval of the Ministry of Health for its new facility. The sterile department was designed to meet the standard of the United States Food and Drug Administration and was opened in February 1997. The firm distributes its products through Ophir & Shalpharm to institutional users such as Israel Health Funds, hospitals and government health facilities. Other subsidiaries include Vitamed Pharmaceutical Industry Ltd., CenterPharm, RITE, Talmor, BARBARA WOLF Ltd. and Madad.

REKA Intrinsic Value
2 330.53 ILS
Undervaluation 41%
Intrinsic Value
Price
R

See Also

What is Rekah Pharmaceutical Industry Ltd's Cash from Financing Activities?
Cash from Financing Activities
-55m ILS

Based on the financial report for Jun 30, 2024, Rekah Pharmaceutical Industry Ltd's Cash from Financing Activities amounts to -55m ILS.

What is Rekah Pharmaceutical Industry Ltd's Cash from Financing Activities growth rate?
Cash from Financing Activities CAGR 1Y
-196%

Over the last year, the Cash from Financing Activities growth was -196%.

Back to Top